Eder Therapeutics and XCubeBio Partner to Establish Joint NewCo for Global Development and Future Market Entry ActivitiesSAGUENAY, Quebec and ZUG, Switzerland, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Eder Therapeutics, a Canadian biopharmaceutical company focused on rare genetic disorders and XCubeBio AG, a biotechnology platform company focused on accelerating successful international market entry for innovative therapeutics, today announced their intention to form a jointly owned entity to coordinate clinical development and regional engagement across Europe and select international markets.
